The Drug Enforcement Administration is preparing to establish a separate federal marijuana production quota system for cannabis products classified under Schedule III, marking another important step in the implementation of the federal government’s new medical marijuana regulations. In a notice released November 9, 2026, the agency confirmed that it is developing production limits for qualifying medical marijuana, cannabis extracts, and naturally derived THC products following the Justice Department’s decision earlier this year to move certain state-regulated medical cannabis activities out of Schedule I. The announcement provides new insight into how federal officials intend to oversee marijuana cultivation and manufacturing as the country transitions toward a more complicated regulatory framework.
The development comes alongside the DEA’s proposed 2027 production quotas for Schedule I and Schedule II controlled substances, which maintain existing limits for marijuana that remains federally classified under Schedule I. Although the agency has not yet established specific Schedule III cannabis production quantities, it confirmed that a separate proposal will be published once officials determine the nation’s legitimate medical and scientific requirements. The distinction is significant because federally registered medical marijuana businesses will operate under a different regulatory system from recreational cannabis companies, which remain outside the scope of the April 2026 rescheduling order. With more than 900 medical marijuana dispensaries recently receiving federal registrations, the new quota framework could become one of the most consequential changes affecting the future of federally regulated cannabis production.
DEA Announces Separate Production Quotas for Schedule III Marijuana
The DEA’s latest announcement appears in its proposed 2027 aggregate production quotas, a comprehensive regulatory document establishing the quantities of certain controlled substances that may be manufactured in the United States for authorized medical, scientific, research, and industrial purposes. Signed November 3 by DEA Administrator Terrance Cole, the notice was made available for public inspection on November 9 and is scheduled for publication in the Federal Register on November 10. While most of the document addresses existing Schedule I and II substances, a separate section explains how marijuana’s recent partial rescheduling requires the development of an additional quota system.
According to the agency, federal officials are currently evaluating available data and methodologies to estimate legitimate production requirements for newly classified Schedule III marijuana products. The process involves three distinct categories: marijuana itself, marijuana extracts, and naturally derived delta-9-tetrahydrocannabinols. These substances received new federal drug identification codes under the April rescheduling order, allowing the DEA to distinguish qualifying medical cannabis products from marijuana that remains in Schedule I. The agency stated that it will issue another Federal Register notice once it determines proposed production quantities. No specific Schedule III marijuana production limits or publication date have been announced.
Existing Marijuana Production Limits Remain Unchanged for 2027
While the Schedule III quota system remains under development, the DEA is proposing to maintain its existing production limits for marijuana classified under Schedule I. The agency’s 2027 proposal establishes an aggregate quota of 6,675,000 grams, equivalent to 6,675 kilograms, of marijuana. It also proposes allowing 1,000,000 grams of marijuana extract, 1,523,040 grams of delta-9-THC, and 1,166,130 grams of other tetrahydrocannabinols under the applicable Schedule I categories. These quantities are unchanged from the corresponding 2026 levels and are intended to support federally authorized activities, particularly scientific research and the manufacture of products permitted under existing controlled-substance regulations.
The proposed Schedule I figures should not be interpreted as production limits for the entire American cannabis industry. State-licensed recreational marijuana businesses generally operate outside the federally authorized controlled-substance system, meaning their cultivation and sales are not legitimized or directly allocated through these federal quotas. Likewise, the existing Schedule I limits do not establish the amount of marijuana that registered medical cannabis producers may eventually manufacture under Schedule III. Those operations will be addressed through the separate quota system currently being developed. This distinction reflects the unusual legal environment created by partial rescheduling, in which the same cannabis plant may receive different federal treatment depending on whether it is handled through a qualifying medical program or another commercial channel.
April 2026 Rescheduling Order Creates New Federal Cannabis Framework
The development follows a major federal policy change announced by the Justice Department on April 23, 2026. Acting Attorney General Todd Blanche issued an order moving FDA-approved marijuana-containing products and cannabis products regulated under qualifying state medical marijuana licenses into Schedule III of the Controlled Substances Act. The order, which became effective April 28, also established an expedited federal registration pathway for eligible medical marijuana businesses. The decision followed President Donald Trump’s December 2025 executive order directing federal officials to accelerate medical cannabis rescheduling and research opportunities.
Schedule III recognizes accepted medical uses while maintaining federal controls over manufacturing, distribution, dispensing, and possession. However, the April order did not remove marijuana entirely from federal drug schedules or legalize recreational cannabis nationwide. Products and activities outside its defined medical framework generally remain subject to Schedule I restrictions, while broader marijuana rescheduling continues through a separate administrative proceeding. The DEA’s new production quota announcement reinforces this distinction by establishing plans to regulate medical cannabis cultivation independently from marijuana that remains in Schedule I. For businesses, the resulting system introduces new opportunities for federal recognition alongside additional regulatory obligations that differ from traditional state cannabis licensing.
International Drug Treaties Require Federal Marijuana Production Controls
One of the most important reasons for creating Schedule III marijuana production quotas involves the United States’ obligations under international drug control agreements. The Single Convention on Narcotic Drugs of 1961 requires participating countries to regulate cannabis production for authorized purposes and prevent excessive manufacturing or accumulation beyond legitimate needs. Among its requirements are licensing systems for manufacturers and distributors, government oversight of cultivation, and production controls intended to prevent diversion into unauthorized markets. These obligations continue to apply to cannabis even when its classification changes under domestic law.
Under the federal Controlled Substances Act, annual aggregate production quotas ordinarily apply to Schedule I and Schedule II substances rather than most Schedule III medications. Marijuana therefore presents an unusual situation because international treaty requirements continue to impose additional controls despite the substance’s partial movement to a less restrictive domestic classification. The DEA’s April rescheduling order established that qualifying medical cannabis would remain subject to production oversight consistent with those treaty obligations. The new notice provides further confirmation that federal officials intend to implement those requirements through a dedicated quota structure instead of simply allowing registered cultivators to manufacture unrestricted quantities.
How Federal Marijuana Production Quotas Will Be Determined
Developing a national medical marijuana production quota requires the DEA to estimate how much cannabis is necessary to satisfy legitimate medical and scientific demand. Under its existing quota procedures, the agency considers historical manufacturing and distribution volumes, inventories, projected demand, diversion risks, anticipated research requirements, and information provided by federal and state health authorities. Additional considerations may include production efficiency, product stability, manufacturing disruptions, and the availability of raw materials. The objective is to establish quantities sufficient to meet authorized needs without encouraging excessive production or creating unnecessary shortages.
Applying these methods to medical cannabis presents challenges because the American marijuana industry has developed primarily through state licensing systems rather than a unified federal pharmaceutical distribution network. States maintain different patient eligibility rules, cultivation regulations, product limits, testing requirements, and reporting systems. Some programs serve large patient populations and support extensive commercial operations, while others restrict qualifying conditions or permitted cannabis formulations. The DEA must determine which information provides a reliable estimate of legitimate national demand while accounting for the differences between raw flower, processed extracts, and concentrated THC products. Inaccurate estimates could create problems for registered manufacturers, potentially restricting supply or allowing production levels that exceed actual medical requirements.
More Than 900 Medical Marijuana Dispensaries Receive Federal Registration
The quota announcement follows another major development in federal medical cannabis regulation. On October 30, the Justice Department confirmed that the DEA had begun issuing federal registrations to more than 900 medical marijuana dispensaries operating in Alabama, Florida, Mississippi, South Dakota, Texas, Virginia, and West Virginia. These approvals represent the first large wave of registrations granted under the April rescheduling order. Each qualifying dispensary must satisfy federal requirements, including security, inventory controls, recordkeeping, and a pre-registration investigation. State licensing alone does not automatically provide federal authorization.
The agency is also reviewing applications submitted by medical marijuana manufacturers and distributors, which are responsible for supplying products to registered dispensaries. These applications involve additional requirements, including facility inspections, production controls, and quota determinations. Nearly 7,000 businesses initially appeared on the DEA’s list of timely applicants, demonstrating substantial industry interest in the new federal framework. Manufacturers may face a more complicated transition than retailers because cultivation and processing volumes must eventually align with the new production quota system. The DEA’s simultaneous development of registration procedures and production estimates suggests that these regulatory responsibilities are closely connected as the federal medical cannabis system expands.
New Quotas Could Reshape Medical Marijuana Cultivation and Supply Chains
The establishment of federal production quotas could have significant implications for medical marijuana cultivators and processors that have historically operated under state authorization. Many cannabis producers currently plan their cultivation schedules according to state licensing requirements, wholesale demand, available growing space, and anticipated product sales. Federal quota restrictions could introduce another consideration by limiting the amount of marijuana that qualifying manufacturers may produce during a specified period. Registered businesses may need to demonstrate that their proposed output corresponds to legitimate medical requirements while maintaining records that allow regulators to monitor production and distribution.
Additional requirements could influence relationships between cultivators, extraction facilities, wholesalers, and dispensaries. A manufacturer operating under Schedule III may need to ensure that products move through federally authorized channels and that trading partners possess appropriate registrations or qualify under transitional provisions. The DEA recently instructed participating medical marijuana businesses to establish compliant supply-chain relationships by November 29, 2026, subject to specified exceptions. These requirements create challenges for vertically integrated companies operating both medical and recreational businesses, particularly when cultivation facilities, inventory systems, and employees serve multiple markets. The eventual quota structure will help determine how easily registered businesses can maintain existing production levels while satisfying federal oversight.
Federal Rescheduling Could Bring Important Tax and Research Benefits
Federal recognition of qualifying medical marijuana activities may also produce substantial financial consequences. Section 280E of the Internal Revenue Code generally prohibits businesses dealing in Schedule I or II controlled substances from deducting many ordinary operating expenses. Because Section 280E does not apply to Schedule III substances, qualifying medical marijuana operations may become eligible for deductions associated with expenses such as payroll, rent, and administration. However, companies serving both medical and recreational customers must consider how federal tax treatment applies to their different activities. Moving medical cannabis into Schedule III does not automatically eliminate restrictions affecting recreational marijuana operations.
Scientific research could also benefit from the developing framework. Researchers have long faced administrative difficulties obtaining marijuana products and conducting studies under Schedule I requirements. Federal recognition of specific medical cannabis activities may improve access to regulated research materials and expand opportunities to investigate cannabinoids for chronic pain, neurological disorders, and other potential applications. Nevertheless, research involving human participants remains subject to applicable scientific, ethical, and federal drug approval requirements. The DEA’s quota system must balance these research needs with existing medical demand, ensuring that authorized investigators can obtain appropriate products without creating unnecessary obstacles or weakening controls intended to prevent diversion.
DEA Proposes Higher Psychedelic Production Quotas Alongside Marijuana Changes
The broader 2027 production quota proposal also reflects changing federal priorities involving psychedelic research. The DEA is seeking substantial increases in the authorized production of certain substances being investigated for potential psychiatric applications. Its proposed ibogaine quota would rise from 210 grams in 2026 to 12,002 grams in 2027, while the MDMA quota would increase from 12,000 grams to 33,296 grams. The agency is also proposing higher limits for psilocybin and psilocyn, reflecting interest in research involving compounds that may have applications for treatment-resistant depression, post-traumatic stress disorder, and other medical conditions.
These changes do not establish that psychedelic substances have received general approval for medical use or that their therapeutic effectiveness has been conclusively demonstrated. Instead, the proposed increases are intended to support expanding scientific investigations and authorized manufacturing requirements. The developments provide broader context for the agency’s approach to marijuana regulation, demonstrating how federal production controls can change in response to research activity and emerging medical evidence. While cannabis has followed a different legal and commercial development path, both areas illustrate the growing importance of aligning controlled-substance regulations with legitimate research requirements.
Broader Federal Marijuana Rescheduling Remains Unfinished
Although qualifying medical marijuana activities have already moved into Schedule III, the federal government continues considering whether marijuana outside the April order should receive similar treatment. The broader administrative proceeding began with a proposal to transfer marijuana from Schedule I to Schedule III and has involved extensive legal arguments, scientific assessments, and public participation. Following changes to the process earlier in 2026, the DEA conducted an evidentiary hearing between June 29 and July 15. Chief Administrative Law Judge Derek Julius is expected to provide findings and recommendations before DEA Administrator Terrance Cole makes a final determination.
A broader rescheduling decision could significantly alter the relationship between federal law and state-regulated cannabis markets, although moving marijuana to Schedule III would not itself establish nationwide recreational legalization. Federal manufacturing, distribution, registration, and product approval requirements would continue to apply, and separate questions involving commercial sales, banking, taxation, and interstate transportation would remain. The pending proceeding also means that the eventual scope of federal marijuana production regulation may continue evolving. For now, the new quota proposal addresses the existing distinction between qualifying Schedule III medical cannabis and marijuana activities that remain under Schedule I controls.
What Happens Next for DEA Marijuana Production Quotas?
The DEA’s proposed 2027 Schedule I and II production quotas are scheduled for publication on November 10, opening a 30-day public comment period before the agency establishes final quantities. Regulators may consider submitted information, revise proposed levels, or hold additional proceedings if warranted. However, the separate Schedule III marijuana quotas have not yet been released and are not part of the published numerical proposal. The agency must first complete its evaluation of legitimate medical production requirements and determine appropriate quantities for marijuana, marijuana extracts, and naturally derived delta-9-THC within the new federal framework.
For medical cannabis businesses, the coming months could determine how federal registration and production requirements affect long-term operations. Cultivators will need greater clarity about manufacturing limits, distributors must establish compliant supply relationships, and dispensaries will depend on authorized producers to maintain adequate inventories for registered patients. Regulators must balance the need for oversight against the practical realities of a medical cannabis industry that has developed over decades under different state systems. The success of the transition will depend partly on whether federal production estimates accurately reflect medical demand and whether administrative requirements can be implemented without unnecessary market disruptions.
The November 9 announcement represents another meaningful step in the gradual transformation of federal marijuana policy. Rather than simply reclassifying certain cannabis products, the DEA is developing the regulatory infrastructure needed to oversee their legal production and distribution. Separate Schedule III quotas will create a new mechanism for measuring and controlling federally recognized medical marijuana manufacturing while preserving existing restrictions on cannabis outside the qualifying medical framework. Although the final production limits remain unknown, the agency’s latest action demonstrates that medical marijuana rescheduling is moving beyond legal classification toward practical federal implementation, with potentially lasting consequences for cultivators, researchers, dispensaries, and patients throughout the United States.
